Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00240448 · ClinicalTrials.gov registry record · Phase 4

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

A Phase 4 study, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 4
Development phase
1,109
Enrollment target

NCT00240448: Completed Phase 4 study, sponsored by Boehringer Ingelheim.

NCT00240448 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,109 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (114% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00240448, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 4
Development phase
1,109 participants
Enrollment target

Study Summary

The primary objective of this study is to compare the effectiveness of telmisartan 80 mg/hydrochlorothiazide 25 mg \[Micardis HCT\] to valsartan 160 mg/hydrochlorothiazide 25 mg \[Diovan HCT\] and placebo in the treatment of Stage 1 and Stage 2 hypertension.

Interventions

  • DRUG placebo
  • DRUG telmisartan 80 mg/hydrochlorothiazide 25 mg
  • DRUG valsartan 160 mg/hydrochlorothiazide 25 mg

Trial Details

FieldValue
Enrollment Target 1,109 participants
Start Date 2003-09
Phase Phase 4
Boehringer Ingelheim

515 total trials

What the finished NCT00240448 record still lists

NCT00240448 is an interventional study that assigns participants to a tested intervention. Its 1,109 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (114% higher).

The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.

NCT00240448 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00240448 about?

NCT00240448 is a clinical study titled "A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients". The primary objective of this study is to compare the effectiveness of telmisartan 80 mg/hydrochlorothiazide 25 mg \[Micardis HCT\] to valsartan 160 mg/hydrochlorothiazide 25 mg \[Diovan HCT\] and placebo in the treatment of Stage 1 and Stage 2 hypertension.

What is the current status of trial NCT00240448?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,109 participants. The study started on 2003-09.

What interventions are being tested in trial NCT00240448?

The interventions under investigation include: placebo (DRUG), telmisartan 80 mg/hydrochlorothiazide 25 mg (DRUG), valsartan 160 mg/hydrochlorothiazide 25 mg (DRUG).

Who is sponsoring clinical trial NCT00240448?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00240448's enrollment target sits among peer trials

1,109 65th of 2000 higher than 1,936 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00710112 · 1,100 participants

    Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants

  • NCT02688517 · 1,100 participants

    Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

  • NCT04743765 · 1,100 participants · NA

    HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

  • NCT05638581 · 1,100 participants · Phase 3

    Trauma Resuscitation With Low-Titer Group O Whole Blood or Products

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00240448, the US trial registry maintained by the National Library of Medicine. NCT00240448 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.